Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Increased by WINTON GROUP Ltd

WINTON GROUP Ltd grew its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 94.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,005 shares of the biopharmaceutical company’s stock after buying an additional 9,210 shares during the period. WINTON GROUP Ltd’s holdings in Cytokinetics were worth $894,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp increased its stake in Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 374 shares during the last quarter. Centricity Wealth Management LLC bought a new position in Cytokinetics in the fourth quarter worth about $29,000. AlphaQuest LLC grew its holdings in shares of Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp raised its position in shares of Cytokinetics by 62.1% during the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 671 shares during the period. Finally, Blue Trust Inc. boosted its position in Cytokinetics by 85.8% during the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 842 shares during the period.

Cytokinetics Stock Up 0.5 %

Shares of CYTK stock opened at $43.19 on Friday. The company has a market capitalization of $5.11 billion, a price-to-earnings ratio of -8.03 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The stock’s 50 day simple moving average is $45.75 and its 200 day simple moving average is $49.55. Cytokinetics, Incorporated has a twelve month low of $40.53 and a twelve month high of $75.71.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, research analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Analyst Upgrades and Downgrades

CYTK has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a report on Thursday, February 6th. Stifel Nicolaus assumed coverage on Cytokinetics in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 target price for the company. Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Finally, Morgan Stanley set a $67.00 price objective on Cytokinetics in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Insider Transactions at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $45.92, for a total value of $91,840.00. Following the sale, the executive vice president now owns 116,071 shares of the company’s stock, valued at $5,329,980.32. The trade was a 1.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Andrew Callos sold 3,341 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the transaction, the executive vice president now owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. This represents a 4.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,834 shares of company stock worth $1,949,275. 3.40% of the stock is currently owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.